Humacyte, Inc. (NASDAQ:HUMA) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET

Company Participants

Lauren Marek - LifeSci Advisors
Laura Niklason - President and CEO
Dale Sander - CFO and Chief Corporate Development Officer

Conference Call Participants

Ryan Zimmerman - BTIG
Josh Jennings - TD Cowen & Company
Kristen Kluska - Cantor Fitzgerald
Bruce Jackson - Benchmark Company
Vernon Bernardino - H.C. Wainwright

Operator

Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2024 Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded.

I will now turn the call over to Lauren Marek with LifeSci Advisors. Please go ahead.

Lauren Marek

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which after filing may be accessed from the Investors page of the Humacyte website.

Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer, and Dale Sander, Chief Financial Officer and Chief Corporate Development Officer. Dr. Niklason will provide a summary of the company's progress during the quarter in recent weeks, and Dale will review the company's financial results for the quarter ended September 30, 2024. Following their prepared remarks, the management team will be available for your questions.

I will now turn the call over to Dr. Niklason.

Laura Niklason

Thank you, Lauren. Good morning, everyone, and thank you for joining us for our third quarter, 2024, financial results and business update call. This has been a very productive time for Humacyte.

While the FDA review of our ATEV BLA in vascular trauma is still ongoing, the entire Humacyte team continues to engage in commercial preparation to support our planned U.S. market launch, if approved. Importantly, we submitted our new technology add-on payment, or NTAP, application to the Centers for Medicare and Medicaid Services in early October.